No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HOLX240517C70000
- 6.80
- 0.000.00%
15min DelayTrading May 6 10:56 ET
0.00High0.00Low
0.00Open6.80Pre Close0 Volume114 Open Interest70.00Strike Price0.00Turnover44.78%IV0.38%PremiumMay 17, 2024Expiry Date5.61Intrinsic Value100Multiplier7DDays to Expiry1.19Time Value100Contract SizeAmericanOptions Type0.8940Delta0.0376Gamma12.82Leverage Ratio-0.0669Theta0.0128Rho11.46Eff Leverage0.0199Vega
Intraday
- 5D
- 1D
News
Hologic Is Maintained at Buy by Argus Research
Hologic Is Maintained at Buy by Argus Research
Argus Adjusts Price Target on Hologic to $95 From $89
Hologic (HOLX) has an average rating of outperform and price targets ranging from $70 to $95, according to analysts polled by Capital IQ.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)
A Dive Into Hologic (HOLX) International Revenue Trends and Forecasts
Here Is What to Know Beyond Why Hologic, Inc. (HOLX) Is a Trending Stock
Hologic, Inc.'s (NASDAQ:HOLX) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 38.3x Hologic, Inc. (NASDAQ:HOLX) may be sending very bearish signals at the moment, given that almost half of all companies in the United States have P/E
Comments
$Hologic(HOLX.US$ Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography 3 MINUTES AGO, 2:07 PM EDT VIA BUSINESSWIRE Collaboration Includes Robust Education and Training to Support Radiologists and Imaging Specialists Bayer and Hologic, Inc. (NASDAQ:HOLX) today announced a first-of-its-kind collaboration to deliver a coordinated solution for contrast-enhanced mammography (CEM). The two ...
1
Multiple insiders selling shares could be a red flag. The absence of insider purchases and significant selling over the last three months may suggest insiders believe the shares are overpriced. Despite high insider ownership, the lack of buying and significant selling raises concerns about the company.
Undervalued Hologic presents opportunity to accumulate stocks. Investors cautioned to consider financial health. Company's outlook suggests further growth not reflected in share price.
I've been eyeing the news on this sector and it finally gained some traction. I agree Dare is another good one
Gapping up
$Visa(V.US$ +1.1%, $MasterCard(MA.US$ +1.7% (Keybanc upgraded their ratings to overweight from from sector weight.)
$Zillow-C(Z.US$ +4% (Bank of America double upgraded the stock to buy, citing its improved growth outlook despite a challenging macroeconomic environment.)
$Hologic(HOLX.US$ +2.8% (The women's diagnostics provider reported fiscal first quarter revenue Sunday that topped its most recent guidance and Wall Str...
$Visa(V.US$ +1.1%, $MasterCard(MA.US$ +1.7% (Keybanc upgraded their ratings to overweight from from sector weight.)
$Zillow-C(Z.US$ +4% (Bank of America double upgraded the stock to buy, citing its improved growth outlook despite a challenging macroeconomic environment.)
$Hologic(HOLX.US$ +2.8% (The women's diagnostics provider reported fiscal first quarter revenue Sunday that topped its most recent guidance and Wall Str...
10
Read more